The biotechnology firm, specializing in the creation of microbial and fungal-based gene expression technology platforms, appears poised to potentially transform the pharmaceutical sector with its exceptionally innovative solutions. A key focus for Dyadic International Inc. (NASDAQ: DYAI) currently revolves around a significant project aimed at efficiently developing proteins for global health.
The corporation is actively addressing the escalating global demand for proteins, catering to both human and animal health needs. Headquartered in Jupiter, Florida, this international biotech firm operates a satellite office in the Netherlands. At the core of the company’s endeavour’s is the biopharmaceutical gene expression platform known as C1. Functioning as a microorganism, C1 facilitates the cost-effective development and large-scale production of proteins. Moreover, this platform holds the potential to refine proteins into a safer expression system, expediting the development of targeted proteins. This advancement not only enhances the efficacy of certain biologic vaccines but also reduces production expenses while optimizing the performance of therapeutic proteins.
At present, the company is exclusively dedicated to implementing its patented and proprietary C1 technology platform. This platform is utilized for the development of pharmaceutical applications for both animal and human use. The company recently disclosed that the C1 platform stands as one of its two primary assets. Furthermore, there are plans to explore research collaborations with pharmaceutical companies in both the animal and human health sectors.
The objective of these research collaborations is to harness the capabilities of the C1 cell protein production platform to facilitate the creation of innovative drugs and vaccines. The C1 platform holds significant promise as a key asset for Dyadic in its pursuit of revolutionizing the industry. It is crucial to note that Dyadic International has dedicated over 20 years to advancing the CI platform. During this period, the company has invested upwards of $100 million in the development of C1. Importantly, Dyadic International’s original industrial technology business was divested to Dupont.
Dyadic International, Inc. (NASDAQ: DYAI) Trading consistently above its 30-day and 60-day daily volume averages, closing above the 20-day moving average (DMA) on Friday, December 28, 2023, and situated below the 50 and 200 DMA’s, with a 52-week peak at $2.40, indicates consolidation and hints at a potential shift towards an upward trajectory for DYAI. Given these signals, closely monitoring DYAI as a stock is advisable in the current period and the weeks ahead.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: \”Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development\”